^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

NRAS amplification

i
Other names: NRAS1, HRAS1, N-Ras Protein Part 4, Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog, NRAS, Neuroblastoma RAS Viral Oncogene Homolog, NRAS Proto-Oncogene, GTPase
Entrez ID:
Related biomarkers:
16d
Amplification of mutant NRAS in melanocytic tumors with features of Spitz tumors. (PubMed, Mod Pathol)
Follow-up data were available for five patients, with a median period of 4.2 years (ranging from 1 to 9 years), during which no recurrences or metastases were reported. Our series highlights a clinicopathologically and molecularly distinctive subset of NRAS-mutated tumors with amplification of the mutant NRAS allele.
Journal
|
NRAS (Neuroblastoma RAS viral oncogene homolog)
|
NRAS mutation • NRAS amplification
8ms
Integrative CRISPR Activation and Small Molecule Inhibitor Screening for lncRNA Mediating BRAF Inhibitor Resistance in Melanoma. (PubMed, Biomedicines)
Among them there are long non-coding RNAs (lncRNAs), but these remain functionally poorly understood. Here, we conduct a comprehensive, unbiased, and integrative study of lncRNA expression, coupled with a Clustered Regularly Interspaced Short Palindromic Repeats/Cas9-mediated activation (CRISPRa) and small molecule inhibitor screening for BRAF inhibitor resistance to expand the knowledge of potentially druggable lncRNAs, their function, and pave the way for eventual combinatorial treatment approaches targeting diverse pathways in melanoma.
Journal • IO biomarker
|
NRAS (Neuroblastoma RAS viral oncogene homolog)
|
NRAS amplification
over2years
Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC. (PubMed, NPJ Precis Oncol)
Analysis of downstream signaling revealed extracellular signal-related kinase activation that could only be eliminated by trametinib treatment, while Akt activation could be modulated by various combinations of MET, EGFR, and PI3K inhibitors. The combination of an EGFR inhibitor with a MEK inhibitor was identified as a possible treatment option to overcome drug resistance related to NRAS gene amplification.
Preclinical • Journal
|
EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase) • NRAS (Neuroblastoma RAS viral oncogene homolog)
|
EGFR mutation • MET amplification • NRAS amplification
|
Mekinist (trametinib)
over2years
Gene expression profiling utilizing extremely sensitive CDNA arrays and enrichment-based network study of major bone cancer genes. (PubMed, J Res Med Sci)
CDKN2A gene amplifications have been observed in virtually all tumor specimens. This study points to a recognizable evidence of novel superimposed pathways mechanisms strongly linked to cancer.
Journal
|
BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • AKT1 (V-akt murine thymoma viral oncogene homolog 1)
|
TP53 mutation • BRAF mutation • PIK3CA mutation • NRAS amplification • BRAF amplification
over3years
Macrophages Promote Growth of Squamous Cancer Independent of T cells. (PubMed, J Dent Res)
Taken together, our study revealed that macrophages contribute to SCC expansion through interactions with tumor cells but are dispensable for SCC metastasis. Our study provides novel insights into understanding the contributions and limitations of TAMs in SCC progression.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • SMAD4 (SMAD family member 4)
|
NRAS amplification • SMAD4 deletion • KRAS deletion